Evolent Health, Inc (NYSE:EVH) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other equities analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Evolent Health from a “hold” rating to a “sell” rating in a report on Thursday. Cowen and Company restated an “outperform” rating and set a $33.00 target price (down previously from $35.00) on shares of Evolent Health in a report on Wednesday. Robert W. Baird set a $35.00 target price on shares of Evolent Health and gave the company a “buy” rating in a report on Tuesday. ValuEngine lowered shares of Evolent Health from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Finally, Leerink Swann restated an “outperform” rating and set a $32.00 target price (up previously from $30.00) on shares of Evolent Health in a report on Monday, June 19th. Three analysts have rated the stock with a sell rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $29.90.

Shares of Evolent Health (NYSE:EVH) traded up 4.25% during mid-day trading on Friday, hitting $18.40. The stock had a trading volume of 2,941,142 shares. The stock’s market cap is $1.21 billion. The company’s 50 day moving average price is $24.73 and its 200 day moving average price is $22.68. Evolent Health has a 12-month low of $14.50 and a 12-month high of $27.50.

Evolent Health (NYSE:EVH) last posted its earnings results on Monday, August 7th. The technology company reported ($0.13) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $107.30 million for the quarter, compared to analyst estimates of $104.45 million. Evolent Health had a negative net margin of 17.57% and a negative return on equity of 6.44%. The business’s quarterly revenue was up 89.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.20) EPS. Equities research analysts predict that Evolent Health will post ($0.41) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/12/evolent-health-inc-nyseevh-downgraded-to-sell-at-bidaskclub.html.

In other Evolent Health news, CEO Frank J. Williams sold 114,865 shares of the business’s stock in a transaction on Friday, May 19th. The shares were sold at an average price of $24.30, for a total value of $2,791,219.50. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Nicholas Mcgrane sold 10,495 shares of the business’s stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $26.95, for a total transaction of $282,840.25. The disclosure for this sale can be found here. Insiders sold a total of 10,153,967 shares of company stock worth $253,648,377 in the last quarter. 8.79% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the stock. Handelsbanken Fonder AB bought a new stake in shares of Evolent Health during the first quarter worth about $1,784,000. US Bancorp DE raised its stake in shares of Evolent Health by 0.3% in the first quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock worth $126,000 after buying an additional 19 shares during the period. Tygh Capital Management Inc. raised its stake in shares of Evolent Health by 199.8% in the first quarter. Tygh Capital Management Inc. now owns 314,942 shares of the technology company’s stock worth $7,023,000 after buying an additional 209,876 shares during the period. American Century Companies Inc. raised its stake in shares of Evolent Health by 5.2% in the first quarter. American Century Companies Inc. now owns 162,116 shares of the technology company’s stock worth $3,615,000 after buying an additional 8,020 shares during the period. Finally, First Trust Advisors LP bought a new stake in shares of Evolent Health during the first quarter worth about $735,000. Institutional investors and hedge funds own 73.16% of the company’s stock.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.